Five Prime Therapeutics Inc (FPRX.OQ)
FPRX.OQ on NASDAQ Stock Exchange Global Select Market
6.12USD
2 Jul 2020
6.12USD
2 Jul 2020
Change (% chg)
$-0.29 (-4.52%)
$-0.29 (-4.52%)
Prev Close
$6.41
$6.41
Open
$6.56
$6.56
Day's High
$6.56
$6.56
Day's Low
$6.08
$6.08
Volume
94,733
94,733
Avg. Vol
139,780
139,780
52-wk High
$7.21
$7.21
52-wk Low
$1.76
$1.76
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.62 | December | 4 Jul 2020 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 3 | 2 | 2 | 2 |
| (2) OUTPERFORM | 1 | 1 | 1 | 1 |
| (3) HOLD | 3 | 4 | 4 | 4 |
| (4) UNDERPERFORM | 1 | 1 | 1 | 1 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.25 | 2.50 | 2.50 | 2.50 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-20 | 7 | 4.25 | 8.00 | 0.00 | 17.83 |
| Quarter Ending Dec-20 | 7 | 5.51 | 15.00 | 0.00 | 37.53 |
| Year Ending Dec-20 | 7 | 22.75 | 41.50 | 8.40 | 52.15 |
| Year Ending Dec-21 | 8 | 12.66 | 20.00 | 0.00 | 79.21 |
| Earnings (per share) | |||||
| Quarter Ending Sep-20 | 7 | -0.62 | -0.40 | -0.74 | -0.66 |
| Quarter Ending Dec-20 | 7 | -0.57 | -0.32 | -0.79 | -0.10 |
| Year Ending Dec-20 | 7 | -2.43 | -1.78 | -2.81 | -2.88 |
| Year Ending Dec-21 | 8 | -2.15 | -1.52 | -2.85 | -2.58 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-20 | 6.28 | 8.41 | 2.14 | 34.06 |
| Quarter Ending Dec-19 | 4.65 | 3.21 | 1.44 | 30.94 |
| Quarter Ending Sep-19 | 5.23 | 2.98 | 2.25 | 42.94 |
| Quarter Ending Jun-19 | 7.73 | 3.33 | 4.40 | 56.90 |
| Quarter Ending Mar-19 | 4.79 | 5.35 | 0.56 | 11.65 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-20 | 4.25 | 4.25 | 4.25 | 3.72 | 17.83 |
| Quarter Ending Dec-20 | 5.51 | 5.51 | 5.51 | 4.38 | 37.53 |
| Year Ending Dec-20 | 22.75 | 22.75 | 22.75 | 18.36 | 52.15 |
| Year Ending Dec-21 | 12.66 | 12.66 | 12.66 | 12.19 | 79.21 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-20 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-20 | 0 | 0 | 0 | 0 |
| Year Ending Dec-20 | 0 | 0 | 0 | 0 |
| Year Ending Dec-21 | 0 | 0 | 0 | 0 |
| Earnings | ||||
Earnings vs. 
Estimates- BRIEF-Five Prime Therapeutics Reports Q1 Loss Per Share Of $0.57
- BRIEF-Redhill Biopharma Strengthens Coverage For Talicia With Preferred Brand Position On Prime Therapeutics Netresults National Formulary
- BRIEF-Five Prime Therapeutics Appoints Tom Civik As Chief Executive Officer
- BRIEF-Five Prime Therapeutics Reports Q4 Loss Per Share $0.89
- BRIEF-Five Prime Therapeutics Licenses Antibodies To Seattle Genetics For Use In Novel Antibody Drug Conjugate Programs